The vast majority of people with cancer develop a good immune response after two doses of COVID-19 mRNA (Pfizer, Modena) vaccine, but a small group of non-responders pose challenges for haematological oncologists, an international study suggests. An analysis of responses to SARS-CoV-2 mRNA vaccines in 131cancer patients, treated at two cancer centres in the US ...
Most cancer patients show good responses to mRNA vaccine
By Michael Woodhead
13 Jul 2021